tetano
Editor, Senior Moderator
Vet Microbiol. 2015 Jul 17. pii: S0378-1135(15)00282-5. doi: 10.1016/j.vetmic.2015.07.020. [Epub ahead of print]
[h=1]Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes.[/h] Li R[SUP]1[/SUP], Chowdhury MY[SUP]2[/SUP], Kim JH[SUP]1[/SUP], Kim TH[SUP]1[/SUP], Pathinayake P[SUP]1[/SUP], Koo WS[SUP]1[/SUP], Park ME[SUP]3[/SUP], Yoon JE[SUP]3[/SUP], Roh JB[SUP]4[/SUP], Hong SP[SUP]4[/SUP], Sung MH[SUP]4[/SUP], Lee JS[SUP]5[/SUP], Kim CJ[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The development of a universal influenza vaccine that provides broad cross protection against existing and unforeseen influenza viruses is a critical challenge. In this study, we constructed and expressed conserved sM2 and HA2 influenza antigens with cholera toxin subunit A1 (CTA1) on the surface of Lactobacillus casei (pgsA-CTA1sM2HA2/L. casei). Oral and nasal administrations of recombinant L. casei into mice resulted in high levels of serum immunoglobulin G (IgG) and their isotypes (IgG1 & IgG2a) as well as mucosal IgA. The mucosal administration of pgsA-CTA1sM2HA2/L. casei may also significantly increase the levels of sM2- or HA2-specific cell-mediated immunity because increased release of both IFN-γ and IL-4 was observed. The recombinant pgsA-CTA1sM2HA2/L. casei provided better protection of BALB/c mice against 10 times the 50% mouse lethal doses (MLD[SUB]50[/SUB]) of homologous A/EM/Korea/W149/06(H5N1) or A/Aquatic bird/Korea/W81/2005 (H5N2) and heterologous A/Puerto Rico/8/34(H1N1), or A/Chicken/Korea/116/2004(H9N2) or A/Philippines/2/08(H3N2) viruses, compared with L. casei harboring sM2HA2 and also the protection was maintained up to seven months after administration. These results indicate that recombinant L. casei expressing the highly conserved sM2, HA2 of influenza and CTA1 as a mucosal adjuvant could be a potential mucosal vaccine candidate or tool to protect against divergent influenza viruses for human and animal.
Copyright ? 2015. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Influenza; Mucosal immunity; surface display
PMID: 26210951 [PubMed - as supplied by publisher]
[h=1]Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes.[/h] Li R[SUP]1[/SUP], Chowdhury MY[SUP]2[/SUP], Kim JH[SUP]1[/SUP], Kim TH[SUP]1[/SUP], Pathinayake P[SUP]1[/SUP], Koo WS[SUP]1[/SUP], Park ME[SUP]3[/SUP], Yoon JE[SUP]3[/SUP], Roh JB[SUP]4[/SUP], Hong SP[SUP]4[/SUP], Sung MH[SUP]4[/SUP], Lee JS[SUP]5[/SUP], Kim CJ[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The development of a universal influenza vaccine that provides broad cross protection against existing and unforeseen influenza viruses is a critical challenge. In this study, we constructed and expressed conserved sM2 and HA2 influenza antigens with cholera toxin subunit A1 (CTA1) on the surface of Lactobacillus casei (pgsA-CTA1sM2HA2/L. casei). Oral and nasal administrations of recombinant L. casei into mice resulted in high levels of serum immunoglobulin G (IgG) and their isotypes (IgG1 & IgG2a) as well as mucosal IgA. The mucosal administration of pgsA-CTA1sM2HA2/L. casei may also significantly increase the levels of sM2- or HA2-specific cell-mediated immunity because increased release of both IFN-γ and IL-4 was observed. The recombinant pgsA-CTA1sM2HA2/L. casei provided better protection of BALB/c mice against 10 times the 50% mouse lethal doses (MLD[SUB]50[/SUB]) of homologous A/EM/Korea/W149/06(H5N1) or A/Aquatic bird/Korea/W81/2005 (H5N2) and heterologous A/Puerto Rico/8/34(H1N1), or A/Chicken/Korea/116/2004(H9N2) or A/Philippines/2/08(H3N2) viruses, compared with L. casei harboring sM2HA2 and also the protection was maintained up to seven months after administration. These results indicate that recombinant L. casei expressing the highly conserved sM2, HA2 of influenza and CTA1 as a mucosal adjuvant could be a potential mucosal vaccine candidate or tool to protect against divergent influenza viruses for human and animal.
Copyright ? 2015. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Influenza; Mucosal immunity; surface display
PMID: 26210951 [PubMed - as supplied by publisher]